icotec ag, based in Altstaetten, Switzerland, develops a new generation of high‑tech implants to treat spinal tumors using its BlackArmor® Carbon/PEEK technology. The company combines technologies and industry expertise to deliver solutions for spine surgeons and their patients. Since receiving FDA clearance in 2019, many designated US cancer centers have adopted BlackArmor® products. Led by CEO Roger Stadler, icotec plans to use new funding to continue growth and strengthen research and development. The company intends to expand its portfolio into underserved indications including spinal infection and osteoporosis. WISTAMA Finanz- und Beteiligungs AG, the family office of the Stadler family that founded the company, remains fully invested as majority shareholder.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024